Registration and Abstract Submission Now Open for the Third BHD Symposium, 11 and 12 May 2011

Now just for a little intermission from the paper commentaries that have graced our recent posts to let you know the exciting news about our Symposium. More details have been finalized, and so we’ve just put up a new page here. Registration and abstract submission are now open, with a deadline of 15 March for both abstracts and the lowest registration prices.    

We’re anticipating a very productive and interesting couple of days, as this time there will also be sessions led by researchers specializing in Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). Given that specialists in BHD, HLRCC and related diseases work in small clusters all over the world, the symposium offers an exceptional occasion to gather together, share recent research and generate new ideas. As usual, the symposium welcomes researchers of all kinds, from biologists to dermatologists, as well as individuals diagnosed with BHD, family members and other interested public.   

It’s also an amazing opportunity to have our symposium in Maastricht. This lively city boasts medieval streets, charming parks, buildings by noted modern architects and the most beautiful bookshop in the world, if you agree with this evaluation from The Guardian. It is also the home of conductor André Rieu, for those of you who adore classical music and waltzes.  

And if you are wondering who is writing this post: I’ve joined the team at the Myrovlytis Trust after studying a Master’s in the history of medicine, science and technology at Imperial College, following a degree in French literature and Classics at Harvard. I’m looking forward to discussions with you, whether introducing interesting events or perhaps commenting on science policy relevant to BHD. – the primary online resource for anyone interested in BHD Syndrome.

The material in this press release comes from the originating research organization. Content may be edited for style and length. Want more? Sign up for our daily email.